Boston Scientific, a cornerstone of global medical device manufacturing, has withdrawn its 2026 financial guidance after a cyberattack introduced a level of operational uncertainty that renders even cautious forecasting unreliable. The breach — whose full scope remains undisclosed — has disrupted the company's ability to plan, produce, and project, forcing a rare public admission that the future, for now, cannot be mapped. In an industry where supply continuity is inseparable from patient care, the silence where guidance once stood carries weight beyond the stock ticker.